How academic centers are trying to keep their promising drug discoveries out of the ‘valley of death’
Scripps Research hatches medicines. Now, it’s looking to spark something else: a model for financial independence.
The biomedical institute has carried programs into clinical trials, and elsewhere, the University of Texas MD Anderson Cancer Center is co-developing companies.
No longer beholden to early-stage pacts with pharmaceuticals, academic centers are trying to do a better job capitalizing on their science. The goal is to ease their reliance on government funding and overcome the “valley of death” in which promising research languishes.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.